EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma.
Davis ID, Long A, Yip S, Espinoza D, Thompson JF, Kichenadasse G, Harrison M, Lowenthal RM, Pavlakis N, Azad A, Kannourakis G, Steer C, Goldstein D, Shapiro J, Harvie R, Jovanovic L, Hudson AL, Nelson CC, Stockler MR, Martin A.
Davis ID, et al. Among authors: kichenadasse g.
Ann Oncol. 2015 Jun;26(6):1118-1123. doi: 10.1093/annonc/mdv078. Epub 2015 Feb 20.
Ann Oncol. 2015.
PMID: 25701452
Free article.
Clinical Trial.